S-P's Aerius reduces allergy symptoms

New data presented at the Congress of the European Academy of Allergology and Clinical Immunology in Barcelona, Spain, demonstrate that US drug major Schering-Plough's Aerius (desloratadine) significantly reduces allergy symptoms, including nasal congestion, sneezing, rhinorrhea, nasal pruritus and ocular pruritus, in patients with intermittent allergic rhinitis who experience symptoms lasting less than four days per week or less than four weeks per year.

According to the study in patients with IAR, those receiving Aerius 5mg for a 15-day treatment period experienced significant reduction in total symptom severity score from baseline versus placebo (-3.01 vs -2.13; p<0.001). Additionally, patients receiving Aerius experienced improvement in symptoms as early as the first day of treatment (p=0.001) and lasting for the full 24-hour dosing period across the entire study (p<0.001).